Search | Page 8 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS

    ... Reliable clinical or molecular predictors of benefit from azacitidine therapy ... whose data was collected in a prospective clinical trial with a longer median follow-up. We found a significant association ...

    Research Article last updated 08/04/2014 - 8:37am.

  2. Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment.

    ... changing MDS environment is raising new challenges in clinical trial design and defining new indications for MDS drugs. Many current ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. First-in Human Clinical Transplant Trial for Severe Aplastic Anemia

    ... cells that underwent ex-vivo T cell depletion. This trial started in 2009 and was the first of its kind for aplastic anemia. It’s ... Position / Title:  Clinical Director Institution:  ...

    Interview last updated 10/04/2017 - 1:36pm.

  4. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

    ... treated with lenalidomide in the MDS-004 clinical trial were retrospectively assessed for p53 expression by ... syndromes. This study is based on data from the MDS 004 trial (clinicaltrials.gov identifier: NCT00179621). ...

    Research Article last updated 04/23/2014 - 12:26pm.

  5. Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.

    ... is expanding rapidly, but limited comparative clinical trial data are available to (i) define the optimal use of azacitidine in ...

    Research Article last updated 07/09/2013 - 3:03pm.

  6. Pharmacotherapy of myelodysplastic syndromes.

    ... molecular pathways that account for disease evolution and clinical heterogeneity is expanded, the arsenal of potential drugs that may ... therapy (approved drug or newer agents still in clinical trial ) is likely to be the most beneficial. While there is no single answer ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Novel therapies for myelodysplastic syndromes.

    ... therapeutic successes have prompted a new wave of clinical trials enrolling patients with myelodysplastic syndromes ... currently in development for MDS, reviewing clinical trial data related to five classes of novel therapeutics: clofarabine, a ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy

    ... while sparing normal cells. Our purpose is to summarize the clinical activity and safety of intravenous (IV) rigosertib delivered by an ... A multinational pivotal phase 3 randomized clinical trial of rigosertib versus best supportive care for patients with ...

    Research Article last updated 05/22/2014 - 10:23am.

  9. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

    ... with >30% blasts have also been shown in a recent phase III trial. Oral administration of azacitidine may enhance patient convenience, ... oral azacitidine (CC-486) have shown biological activity, clinical responses, and tolerability in patients with MDS and AML. Extended ...

    Research Article last updated 12/09/2015 - 8:49am.

  10. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk disease, anemia , and a ... transplantation and participation on a clinical trial . Bone Marrow ...

    Research Article last updated 02/04/2014 - 1:37pm.